Some of the most devastating diseases leading to morbidity and mortality in man have been shown to be associated with lower levels of bioavailable nitric oxide (NO) and s-nitrosoglutathione (GSNO), from atherosclerosis and heart disease to asthma and gastrointestinal disease.
N30 Pharma’s approach to restoring NO balance, by decreasing disease-associated accelerated breakdown of NO’s primary depot, GSNO, has shown itself to be a broadly useful way to treat a wide variety of disease.
To date, pharmacologic inhibition of s-nitrosoglutathione reductase (GSNOR) or GSNOR knockout mice (KO’s) have shown benefit in models of respiratory (asthma and COPD), cardiovascular (hypertension and endothelial dysfunction) and gastrointestinal (inflammatory bowel disease).
In addition to treating the inflammatory effects of disease, increasing bioavailable nitric oxide may promote organ repair and regeneration.
This single approach to modifying the NO pool has shown benefit across multiple disease models, with a safety profile that would suggest wide utility.